Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Spark Capital Advisors(India) Private Limited
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd eyes $2 billion revenues in FY 2015-Business Standard

Monday, 4 Aug 2014 07:34am EDT 

Aurobindo Pharma Ltd:Aims to achieve $2 billion turnover during the current financial year (FY 2015)-Business Standard.FY 2015 revenue of $1.91 bln - Thomson Reuters I/B/E/S. 

Company Quote

1.5 +0.14%
22 Dec 2014